Other Clinical Trial - Reparation of Cartilage Injuries in NCT00263432

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: Completed

Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries to obtain a repair and prevention of secondary osteoarthritis

Recruitment information / eligibility
Status	Completed
Enrollment	10
Est. completion date	July 1, 2015
Est. primary completion date	July 1, 2015
Accepts healthy volunteers	No
Gender	All
Age group	18 Years to 65 Years
Eligibility	Inclusion Criteria: - Important cartilage injury in the knee Exclusion Criteria: - Important axis deviation - Inflammatory joint disorder - Severe obesity

Procedure:
• Human allogenic chondrocytes
Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries

Locations
Country	Name	City	State
Belgium	University Hospital Ghent	Ghent

Sponsors *(2)*
Lead Sponsor	Collaborator
University Hospital, Ghent	University Ghent

Belgium,

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	Healing of the cartilage injuries		After 2 years